• Keine Ergebnisse gefunden

Supplementary Table 1. COVID-19 Symptoms, and results of and CT scan in Patients with PCNSL and COVID-19

N/A
N/A
Protected

Academic year: 2022

Aktie "Supplementary Table 1. COVID-19 Symptoms, and results of and CT scan in Patients with PCNSL and COVID-19"

Copied!
3
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Supplementary Table 1. COVID-19 Symptoms, and results of and CT scan in Patients with PCNSL and COVID-19

     

Variable Total

n = 13 Mild

n = 8 (61.5%) Severe  n = 5 (38.5%)

  Symptoms  – no. (%)  

   Fever 10 (76.9) 5 (62.5) 5 (100)

   Cough 6 (46.2) 5 (62.5) 1 (20)

   Rhinitis 0 (0) 0 (0) 0 (0)

   Fatigue 4 (30.8) 2 (25) 2 (40)

   Myalgia 1 (7.7) 0 (0) 1 (20)

   Shortness of breath 6 (46.2) 2 (25) 4 (80)

     Diarrhoea, nausea and/or vomiting 3 (23.1) 3 (37.5) 0 (0)  

   Anosmia 0 (0) 0 (0) 0 (0)

   Confusion 3 (23.1) 2 (25) 1 (20)

First RT-PCR SARS-CoV2 from pharyngeal swab   – no. (%)

   Negative 3 (23.1) 1 (12.5) 2 (40)

   Positive 10 (76.9) 7 (87.5) 3 (60)

Lung-CT  – no. (%)

   No TDM 5 (38.5) 3 (37.5) 2 (40)

   Lesions < 10 % 2 (15.4) 1 (12.5) 1 (20)

   10-25 % 1 (7.7) 1 (12.5) 0 (0)

   25-50 % 3 (23.1) 3 (37.5) 0 (0)

   > 50 % 2 (15.4) 0 (0) 2 (40)

(2)

Supplementary Table 2. Biological investigations at baseline for Patients with PCNSL and COVID-19

* p < 0.05 for mild vs severe patients (Mann-Withney test)

     

Variable - Median (range) Total

n = 13 Mild

n = 8 (61.5%) Severe  n = 5 (38.5%)

  Hemoglobin level, g/dl 11.35 (8.3-15.4) 11 (9.8-13) 12.6 (8.3-15.4)  

Platelet count, 103/mm3 176.5 (21-450) 167.5 (76-450) 183 (21-244)

Lymphocyte count, /mm3 730 (280-1510) 665 (280-1110) 1290 (620-1510)

Neutrophil count, /mm3 2180 (180-12380) 1695 (180-3710) * 4460 (2430-12380) *

C-reactive protein level, mg/l 11 (1-629) 5.5 (1-112) 97.5 (1-629)

Procalcitonin level, ng/ml 0.11 (0.04-0.33) 0.11 (0.04-0.27) 0.22 (0.11-0.33) Lactate dehydrogenase level, U/l 256 (232-630) 270.5 (232-630) 241 (241-241)

Fibrinogene activity, g/l 5 (3.5-5.7) 5 (3.5-5.7) 4.625 (3.85-5.4)

(3)

Supplementary Figure 1. Evolution of biological parameters after restart of chemotherapy in Patients with PCNSL and COVID-19

A B

C D

E F

COVID-19  diagnosis

Baselin

Day 5 

Day 1 0

5 10 15

Hb (g/dL)

Hemoglobin

Chemotherapy

COVID-19  diagnosis

Baselin

Day 5 

Day 1 0

200 400 600

Platelets (103 mm-3)

Platelets

Chemotherapy

COVID-19  diagnosis

Baselin

Day 5 

Day 1 0

200 400 600 800

Lactate dehydrogenase (U/L)

LDH

Chemotherapy COVID-19 

diagnosis

Baselin

Day 5 

Day 1 0

2000 4000 6000 8000

Lymphocytes (mm-3)

Lymphocytes

Chemotherapy COVID-19 

diagnosis

Baselin

Day 5 

Day 1 0

5000 10000 15000

Neutrophils (mm-3)

Neutrophils

Chemotherapy

COVID-19  diagnosis

Baselin

Day 5 

Day 1 0

20 40 60 80

C reactive protein (mg/L)

CRP

Chemotherapy

Referenzen

ÄHNLICHE DOKUMENTE

Herein, we found that ICU-COVID-19 patients had lower levels of thiol and TAS compared to non-ICU COVID-19 patients and higher TOS and OSI levels, suggesting that the enhancement

We found 0.77% of the cohort to have laboratory-con- firmed COVID-19 positivity, in line with Northern Italy prevalence at the time of the study (i.e., around 0.9%) [4],

Our results show no significant differences in serum total αSyn levels measured on patients with COVID-19 and neu- rological involvement in the form of generalized myoclonus

While there is no clear-cut evi- dence for the effects of cladribine on COVID-19, our cases suggest that cladribine may not increase the risk of COVID- 19 severity in pwMS

A large fraction of patients, after their COVID-19 viral infections, suffer several neu- rological and psychological symptoms of Long COVID-19 for several months, including:

Based on the telephonic conversation with COVID-19 patients who were isolated at home about their loss of smell and data collected from the COVID ward and intensive care unit (ICU)

This transformation could deliver huge benefits for human and planetary health, by slowing the habitat destruction that drives the spread of diseases; reducing

To control for key confounders at the country-level, our analysis includes (1) data on air travel 16 (to capture a possible way of transmission of SARS-CoV-2 across countries